Emergent BioSolutions Inc. (EBS) stock
EBSNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/3072% below fair value
$5.79−0.10 (-1.70%)
Close on Nov 13, 2026Market cap $296.87MP/E –Yield –
Emergent BioSolutions total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Emergent BioSolutions's total debt was $507.70M at Sep 30, 2026. For fiscal 2025 it was $572.10M, down 13.8% from the year before. Over ten years it grew 8.8% a year on average. The highest annual figure on record is $1.41B in fiscal 2022.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $572.10M | -13.8% |
| FY2024 | Dec 31, 2024 | $663.70M | -22.8% |
| FY2023 | Dec 31, 2023 | $860.20M | -38.8% |
| FY2022 | Dec 31, 2022 | $1.41B | +67.2% |
| FY2021 | Dec 31, 2021 | $841.00M | -3.9% |
| FY2020 | Dec 31, 2020 | $874.80M | +7.8% |
| FY2019 | Dec 31, 2019 | $811.30M | +2.1% |
| FY2018 | Dec 31, 2018 | $794.60M | +5785.9% |
| FY2017 | Dec 31, 2017 | $13.50M | -94.6% |
| FY2016 | Dec 31, 2016 | $248.09M | +0.5% |
| FY2015 | Dec 31, 2015 | $246.89M | -1.6% |
| FY2014 | Dec 31, 2014 | $251.00M | +304.8% |
| FY2013 | Dec 31, 2013 | $62.00M | -1.2% |
| FY2012 | Dec 31, 2012 | $62.77M | +5.6% |
| FY2011 | Dec 31, 2011 | $59.45M | +25.4% |
| FY2010 | Dec 31, 2010 | $47.43M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $507.70M | -23.4% |
| Q2 FY2026 | Jun 30, 2026 | $581.80M | -12.9% |
| Q1 FY2026 | Mar 31, 2026 | $573.60M | -13.8% |
| Q4 FY2025 | Dec 31, 2025 | $572.10M | -13.8% |
| Q3 FY2025 | Sep 30, 2025 | $663.10M | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | $667.80M | -22.5% |
| Q1 FY2025 | Mar 31, 2025 | $665.70M | -26.5% |
| Q4 FY2024 | Dec 31, 2024 | $663.70M | -22.8% |
| Q3 FY2024 | Sep 30, 2024 | $662.60M | -23.1% |
| Q2 FY2024 | Jun 30, 2024 | $862.20M | -4.5% |
| Q1 FY2024 | Mar 31, 2024 | $905.90M | -35.2% |
| Q4 FY2023 | Dec 31, 2023 | $860.20M | -38.8% |
| Q3 FY2023 | Sep 30, 2023 | $861.80M | -18.2% |
| Q2 FY2023 | Jun 30, 2023 | $903.20M | +9.5% |
| Q1 FY2023 | Mar 31, 2023 | $1.40B | +67.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.41B | +67.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.05B | +24.1% |
| Q2 FY2022 | Jun 30, 2022 | $825.20M | -3.4% |
| Q1 FY2022 | Mar 31, 2022 | $833.10M | -3.0% |
| Q4 FY2021 | Dec 31, 2021 | $841.00M | -3.9% |
| Q3 FY2021 | Sep 30, 2021 | $848.90M | -3.5% |
| Q2 FY2021 | Jun 30, 2021 | $854.00M | +8.5% |
| Q1 FY2021 | Mar 31, 2021 | $859.10M | +8.9% |
| Q4 FY2020 | Dec 31, 2020 | $874.80M | +7.8% |
| Q3 FY2020 | Sep 30, 2020 | $879.40M | +6.8% |
| Q2 FY2020 | Jun 30, 2020 | $787.20M | -6.3% |
| Q1 FY2020 | Mar 31, 2020 | $789.20M | +6.3% |
| Q4 FY2019 | Dec 31, 2019 | $811.30M | +2.1% |
| Q3 FY2019 | Sep 30, 2019 | $823.40M | +6001.5% |
| Q2 FY2019 | Jun 30, 2019 | $840.50M | +6134.2% |
| Q1 FY2019 | Mar 31, 2019 | $742.50M | +5412.7% |
| Q4 FY2018 | Dec 31, 2018 | $794.60M | +5785.9% |
| Q3 FY2018 | Sep 30, 2018 | $13.50M | -94.6% |
| Q2 FY2018 | Jun 30, 2018 | $13.48M | -94.6% |
| Q1 FY2018 | Mar 31, 2018 | $13.47M | -94.6% |
| Q4 FY2017 | Dec 31, 2017 | $13.50M | -94.6% |
| Q3 FY2017 | Sep 30, 2017 | $248.99M | – |
| Q2 FY2017 | Jun 30, 2017 | $248.69M | – |
| Q1 FY2017 | Mar 31, 2017 | $248.39M | – |
| Q4 FY2016 | Dec 31, 2016 | $248.09M | – |
See a number that looks wrong?